10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG) in a research report report published on Saturday morning,Weiss Ratings reports.

A number of other research firms have also weighed in on TXG. The Goldman Sachs Group reduced their target price on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a report on Wednesday, October 30th. Stephens restated an “overweight” rating and issued a $30.00 price objective on shares of 10x Genomics in a report on Thursday, October 10th. Canaccord Genuity Group cut their target price on 10x Genomics from $32.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, October 10th. Barclays decreased their price target on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, Citigroup cut their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.86.

10x Genomics Trading Down 3.7 %

NASDAQ:TXG opened at $14.45 on Friday. The stock’s 50-day moving average is $15.14 and its 200-day moving average is $17.72. 10x Genomics has a 1-year low of $12.95 and a 1-year high of $51.22. The stock has a market cap of $1.75 billion, a P/E ratio of -9.44 and a beta of 1.85.

Hedge Funds Weigh In On 10x Genomics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its stake in 10x Genomics by 355.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company’s stock worth $8,027,000 after buying an additional 277,355 shares during the period. Lecap Asset Management Ltd. bought a new position in shares of 10x Genomics in the 3rd quarter worth $877,000. Geode Capital Management LLC grew its position in 10x Genomics by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock valued at $41,009,000 after purchasing an additional 42,777 shares during the period. Marshall Wace LLP bought a new stake in 10x Genomics during the 2nd quarter valued at $689,000. Finally, Point72 Asset Management L.P. acquired a new position in 10x Genomics during the third quarter worth $27,778,000. Institutional investors own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.